Evidence map›Paper›PMID 32958719›Full record

ArticleAntimicrobial agents and chemotherapy2020

Successful Development of Bacteriocins into Therapeutic Formulation for Treatment of MRSA Skin Infection in a Murine Model.

Kirill V Ovchinnikov, Christian Kranjec, Tage Thorstensen, Harald Carlsen, Dzung B Diep

Open access · hybridAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Epidermicin NI01 demonstrates potentJAC-antimicrobial resistance · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. The Skin Microbiome: Current Landscape and Future Opportunities.International journal of molecular sciences · 2023
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Kirill V OvchinnikovFaculty of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences, Ås, Norway.ORCID 0000-0002-1565-3990
Christian KranjecFaculty of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences, Ås, Norway.
Tage ThorstensenDepartment of Plant Molecular Biology, Norwegian Institute of Bioeconomy Research, Ås, Norway.
Harald CarlsenFaculty of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences, Ås, Norway.
Dzung B DiepFaculty of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences, Ås, Norway dzung.diep@nmbu.no.ORCID 0000-0001-7661-5501
Norwegian University of Life Sciences · NONorwegian Institute of Bioeconomy Research · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emergence of antibiotic-resistant pathogens has caused a serious worldwide problem in infection treatment in recent years. One of the pathogens is methicillin-resistant

Indexed as

BacteriocinsMethicillin-Resistant Staphylococcus aureusStaphylococcal InfectionsAnimalsAnti-Bacterial AgentsDisease Models, AnimalMiceStaphylococcus aureusAnti-Bacterial AgentsBacteriocinsbacteriocinsgarvicin KSmicrococcin P1MRSAmurine modelskin infection

Identifiers

PMID32958719
PMCPMC7674055
OpenAlexW3087105626

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.